Table 1. Profile of patients included in the study allocated to each sequence of treatment.
| Age (years) | Median (1st / 3rd quartiles) | p-value | |
|---|---|---|---|
| Total | 23.0 (21.0/26.0) | ||
| Placebo/Edotolac | 23.8 (21.0/25.5) | p * = 0.089 | |
| Edotolac/Placebo | 25.0 (22.0/28.0) | ||
| Gender Total | n (%) | ||
| Male | 18 (36.0%) | ||
| Female | 32 (64.0%) | ||
| Placebo/Edotolac | p ** = 0.140 | ||
| Male | 6 (24.0%) | ||
| Female | 19 (76.0%) | ||
| Edotolac/Placebo | |||
| Male | 12 (52.0%) | ||
| Female | 13 (48.0 %) | ||
| Level of anxiety Total | n (%) | ||
| Low anxiety | 44 (88.0%) | ||
| Moderate anxiety | 5 (10.0%) | ||
| High anxiety | 1 (2.0%) | ||
| Placebo/Edotolac | p *** = 0.236 | ||
| Low anxiety | 21 (84.0%) | ||
| Moderate anxiety | 4 (16.0%) | ||
| High anxiety | 0 (0.0%) | ||
| Edotolac/Placebo | |||
| Low anxiety | 23 (92.0%) | ||
| Moderate anxiety | 1 (4.0%) | ||
| High anxiety | 1 (4.0%) | ||
*
Mann-Whitney rank sum test;
**
Fisher Exact test;
***
Chi-square test.